Rivus Pharma raises $132M in series B

Rivus Pharmaceuticals, a biopharmaceutical company focusing on cardio-metabolic health, has raised $132 million in series B financing.

The company will use the funding to further the clinical development of HU6, a drug candidate that treats cardiometabolic disease by addressing obesity. The funding round was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors, according to the Sept. 22 Rivus news release.

"We have an exceptional group of investors who share our vision for bringing a new class of treatments to patients with obesity and cardio-metabolic disease," Rivus President and CEO Allen Cunningham said. "Following encouraging data from our Phase 2a clinical trial in patients with obesity, this financing enables us to advance development of HU6 and a pipeline of Controlled Metabolic Accelerators to address a range of cardio-metabolic conditions."

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars